[go: up one dir, main page]

WO2011145085A3 - Novel antibodies and methods of use for the treatment and diagnosis of cancer - Google Patents

Novel antibodies and methods of use for the treatment and diagnosis of cancer Download PDF

Info

Publication number
WO2011145085A3
WO2011145085A3 PCT/IB2011/052228 IB2011052228W WO2011145085A3 WO 2011145085 A3 WO2011145085 A3 WO 2011145085A3 IB 2011052228 W IB2011052228 W IB 2011052228W WO 2011145085 A3 WO2011145085 A3 WO 2011145085A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
diagnosis
treatment
methods
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/052228
Other languages
French (fr)
Other versions
WO2011145085A2 (en
Inventor
Itai Benhar
Yeshayahu Yakir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Procognia (Israel) Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Procognia (Israel) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Procognia (Israel) Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of WO2011145085A2 publication Critical patent/WO2011145085A2/en
Publication of WO2011145085A3 publication Critical patent/WO2011145085A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/5758—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is related to monoclonal antibodies, fragments, antigen binding portions or fragments thereof, for specific binding to human and/or mouse tumor associated carbohydrate antigens expressed on cancer cells, e.g., human colorectal adenocarcinma, non-small cell lung carcinoma (NSCLC). These antibodies can be used to induce selective cell death in cancer cells and for the treatment of cancer, e.g., NSCLC and/or in the diagnosis of cancers expressing tumor associated carbohydrate antigens in-vitro and in-vivo.
PCT/IB2011/052228 2010-05-21 2011-05-22 Novel antibodies and methods of use for the treatment and diagnosis of cancer Ceased WO2011145085A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34704110P 2010-05-21 2010-05-21
US61/347,041 2010-05-21

Publications (2)

Publication Number Publication Date
WO2011145085A2 WO2011145085A2 (en) 2011-11-24
WO2011145085A3 true WO2011145085A3 (en) 2012-03-01

Family

ID=44532963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/052228 Ceased WO2011145085A2 (en) 2010-05-21 2011-05-22 Novel antibodies and methods of use for the treatment and diagnosis of cancer

Country Status (1)

Country Link
WO (1) WO2011145085A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016178996A1 (en) 2015-05-01 2016-11-10 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
CN107308515B (en) * 2016-09-29 2024-07-05 中国人民解放军总医院 A system for inactivating circulating tumor cells in blood and its application
CN110998327A (en) * 2017-05-12 2020-04-10 温口特 Method for diagnosing cholangiocarcinoma by using methionyl-tRNA synthetase in cholangiocytes
CN113087801B (en) * 2021-04-07 2022-07-05 深圳市核子基因科技有限公司 Kit for jointly detecting lung cancer by using nucleic acid and antibody
WO2023244510A2 (en) * 2022-06-13 2023-12-21 The Regents Of The University Of California Improved glycan-dependent immunotherapeutic bi-specific proteins with longer half-life

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153237A1 (en) * 2007-06-13 2008-12-18 Korea Research Institute Of Bioscience And Biotechnology Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
WO2009028580A1 (en) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
WO2010050528A1 (en) * 2008-10-28 2010-05-06 塩野義製薬株式会社 Anti-muc1 antibody

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503867A (en) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド IL-2 receptor-specific chimeric antibody
CA1341411C (en) 1988-04-16 2002-12-17 Lutz Riechmann Method for producing fv fragments in eukaryotic cells
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GEP20002142B (en) 1991-01-18 2000-06-25 Amgen Inc Method for Treatment and Prevention of TNF Mediated Diseases
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
KR100261941B1 (en) 1994-07-13 2000-07-15 나가야마 오사무 Reconstituted human antibody against human interleukin-8
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6068040A (en) 1998-07-24 2000-05-30 Alpine Overhead Doors, Inc. Slat edge retainer for overhead rolling doors
US6696686B1 (en) 1999-06-06 2004-02-24 Elgems Ltd. SPECT for breast cancer detection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153237A1 (en) * 2007-06-13 2008-12-18 Korea Research Institute Of Bioscience And Biotechnology Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
WO2009028580A1 (en) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
WO2010050528A1 (en) * 2008-10-28 2010-05-06 塩野義製薬株式会社 Anti-muc1 antibody
EP2351777A1 (en) * 2008-10-28 2011-08-03 Shionogi & Co., Ltd. Anti-muc1 antibody

Also Published As

Publication number Publication date
WO2011145085A2 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
WO2011163401A3 (en) Colon and pancreas cancer specific antigens and antibodies
MX2019004193A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer.
NZ603271A (en) Anti-erbb3 antibodies
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
WO2010096434A3 (en) Specific binding proteins and uses thereof
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
WO2011106300A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2009014708A3 (en) Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2011041319A3 (en) Specific binding proteins and uses thereof
WO2015112805A8 (en) Human antibodies to pd-l1
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2014011489A3 (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease
WO2012047317A3 (en) Tumor specific antibodies and uses therefor
WO2010145796A3 (en) Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
NZ619576A (en) Compositions and methods for the treatment of infections and tumors
MX349096B (en) Anti-pd-l1 antibodies and uses thereof.
WO2016160620A3 (en) Car t-cells for the treatment of b7-h4 expressing solid tumors
CA2888908A1 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
GEP201706737B (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
WO2016123591A3 (en) Compositions and methods for treatment and detection of cancers
WO2010045495A3 (en) Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
WO2011145085A3 (en) Novel antibodies and methods of use for the treatment and diagnosis of cancer
NZ607472A (en) Treatment for neoplastic diseases
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11749515

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11749515

Country of ref document: EP

Kind code of ref document: A2